Neurometrix (NASDAQ:NURO) and Endologix (NASDAQ:ELGX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

13.3% of Neurometrix shares are held by institutional investors. 6.4% of Neurometrix shares are held by company insiders. Comparatively, 1.4% of Endologix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Neurometrix and Endologix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurometrix 6.36% 11.77% 7.14%
Endologix -54.72% -173.52% -19.80%

Volatility & Risk

Neurometrix has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Endologix has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Neurometrix and Endologix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurometrix 0 0 1 0 3.00
Endologix 0 4 1 0 2.20

Neurometrix presently has a consensus target price of $5.00, indicating a potential upside of 666.52%. Endologix has a consensus target price of $29.40, indicating a potential upside of 341.44%. Given Neurometrix’s stronger consensus rating and higher probable upside, analysts plainly believe Neurometrix is more favorable than Endologix.

Valuation & Earnings

This table compares Neurometrix and Endologix’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurometrix $16.09 million 0.36 $20,000.00 N/A N/A
Endologix $156.47 million 0.71 -$79.71 million ($7.20) -0.93

Neurometrix has higher earnings, but lower revenue than Endologix.

Summary

Neurometrix beats Endologix on 9 of the 12 factors compared between the two stocks.

Neurometrix Company Profile

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Endologix Company Profile

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.